NAD+ in research: metabolism, ageing and the salvage pathway
What NAD+ is, why it is central to metabolism and sirtuin/PARP signalling, the salvage pathway and its precursors NMN and NR, where the ageing research focus sits, and the delivery problem that shapes the field.
NAD+ occupies an unusual place in the research-compound world. Unlike most peptides, it is not obscure at all — it is one of the most fundamental molecules in cell biology, present in every living cell, and taught in first-year biochemistry. What is newer is the wave of research into what happens when its levels decline, and whether raising them changes anything measurable. This is a summary of the actual science, kept firmly on the research side of the line.
What it is
NAD+ — nicotinamide adenine dinucleotide — is a coenzyme found in all cells. It is not a peptide; it is a dinucleotide, built from two nucleotides joined through their phosphate groups. Its CAS number is 53-84-9 and its molecular weight is 663.43 g/mol. It is grouped with research peptides commercially because it is handled the same way in the lab: a lyophilised compound reconstituted for in-vitro work.
Why it matters biologically
Redox reactions
NAD+ and its reduced form NADH are the central electron carriers of metabolism. They shuttle electrons through glycolysis, the citric acid cycle and oxidative phosphorylation — in other words, they sit at the heart of how cells extract energy from nutrients. This role is textbook and beyond dispute.
Signalling and enzyme cofactor roles
Beyond energy metabolism, NAD+ is consumed as a substrate by several important enzyme families, notably the sirtuins (SIRT1–7) and the PARPs (poly-ADP-ribose polymerases). Because these enzymes use NAD+ up rather than merely borrowing it, cellular NAD+ has to be continuously regenerated. This consumption is the mechanistic hook for much of the ageing-and-metabolism research.
The salvage pathway and precursors
Cells maintain NAD+ largely through the salvage pathway, which recycles nicotinamide back into NAD+ via intermediates including NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Much of the applied research in this area has focused on these precursors rather than on NAD+ itself, precisely because they are smaller and, in principle, easier to deliver into cells. Any serious reading on NAD+ research quickly becomes a reading on NMN and NR as well.
Where the research focus sits
The current research interest clusters around a single observation: tissue NAD+ levels appear to decline with age across many organisms studied, and a number of age-associated metabolic changes track that decline. This has driven a large body of in-vitro and animal work asking whether restoring NAD+, or supplying its precursors, alters those changes. Reported findings in model systems include effects on mitochondrial function, DNA-repair activity (via PARPs) and sirtuin-dependent processes.
What must be stated plainly is that this is an active, unsettled research area. The animal and cell data are genuinely interesting; the human clinical picture is early and far less clear-cut, and results in model organisms have repeatedly failed to translate directly to humans in this field. Extrapolations from a mouse study to human outcomes are extrapolations, not evidence.
The delivery problem
A recurring theme in NAD+ research is that the molecule is large, charged and does not cross cell membranes easily. This is a large part of why the precursors NMN and NR receive so much attention, and why routes of administration are a live methodological question in the literature rather than a solved detail. For in-vitro research the delivery question is handled experimentally; it is mentioned here because it is central to understanding why the field looks the way it does.
Specifications you will see
For research use, NAD+ is typically supplied as a lyophilised powder in higher masses than most peptides — 500mg vials are common, reflecting its lower potency by mass and its different role. Colour can range from off-white to a pale yellow depending on batch and form. Store cold and dry; reconstitute per protocol and use promptly. See our storage guide for handling detail.
Bottom line
NAD+ is not a fringe molecule — its metabolic role is as established as biochemistry gets. The genuinely open questions are downstream: whether age-related NAD+ decline is a cause or a consequence, whether raising NAD+ or its precursors changes meaningful outcomes, and whether any of the striking model-organism results hold up in humans. It is a legitimately interesting research target precisely because those questions are unresolved.
HelixCore stocks NAD+ in 500mg vials, 98%+ purity per source specifications. Every batch is tested for identity and purity and the certificate is published on the product page. UK stock, Royal Mail Tracked 24 dispatch, supplied strictly for in-vitro laboratory research use only — not for human or veterinary use.